🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesGLP-1 and beta-cell preservation — September 2026

GLP-1 and beta-cell preservation — September 2026

NicoleRaleigh Mon, Apr 20, 2026 at 10:50 AM 6 replies 538 viewsPage 1 of 2
NicoleRaleigh
Member
356
1,567
Aug 2024
Raleigh, NC
Apr 20, 2026 at 10:50 AM#1

A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

Because it is glucose-dependent, this class carries a low intrinsic hypoglycaemia risk on its own — the risk arrives when it is combined with insulin or a sulfonylurea, which usually need reducing.

What I am after is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.

Numbers rather than impressions, if you have them.

36 6InsuranceTom, WendyG_ATL, SaraMom3 and 33 others
Reply Quote Save Share Report
Dr.SportsMedIN
Senior Member
1,456
6,789
Feb 2024
Indianapolis, IN
Apr 20, 2026 at 11:26 AM#2
NicoleRaleigh said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

My labs after 9 months on glycaemic control: A1C 5.6%, fasting glucose 81 mg/dL, fasting insulin 4 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 7.7% and fasting glucose was 116 mg/dL. The improvement has been dramatic and consistent.

Last edited: Apr 20, 2026 at 4:26 PM
35 5lisa_labSD, adam_van, Dr.SurgeonPGH and 32 others
Reply Quote Save Share Report
Dr.BariatricHTX
Senior Member
1,456
7,234
Feb 2024
Houston, TX
Apr 20, 2026 at 12:02 PM#3
Dr.SportsMedIN said:
My labs after 9 months on glycaemic control: A1C 5.6%, fasting glucose 81 mg/dL, fasting insulin 4 uIU/mL.

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)1281029286
Insulin (fasting)241686
HOMA-IR4.52.92.01.2
Uric Acid7.66.85.94.9

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 4.5 to near 1.0 is a metabolic transformation.

34 4Dr.EM_Chicago, pete_RVA, CarlaRPh_TPA and 31 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
KristenIndy
Member
623
2,678
May 2024
Indianapolis, IN
Apr 20, 2026 at 12:38 PM#4
NicoleRaleigh said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

Adding a me-too, because a thread of one person's experience is not much use. Posting only so the count is not one.

Last edited: Apr 20, 2026 at 5:38 PM
33 3DataDave, Dr.GutHealth, amsterdam_pete and 30 others
Reply Quote Save Share Report
paige_pharma
Member
289
1,234
Sep 2024
Omaha, NE
Apr 20, 2026 at 3:59 PM#5

Clinical perspective, offered as context rather than as advice.

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 4.8 (insulin resistant) → Current = 1.2 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

32 2lucas_SP_BR, lisa_labSD, adam_van and 29 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register